Last reviewed · How we verify
Azienda Ospedaliero, Universitaria Pisana — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Baricitinib Oral Tablet | Baricitinib Oral Tablet | phase 3 | JAK inhibitor | JAK1, JAK2 | Immunology |
Therapeutic area mix
- Immunology · 1
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AbbVie · 1 shared drug class
- AbbVie Inc. · 1 shared drug class
- Aclaris Therapeutics, Inc. · 1 shared drug class
- Arcutis Biotherapeutics, Inc. · 1 shared drug class
- Beijing Friendship Hospital · 1 shared drug class
- CAGE Bio Inc. · 1 shared drug class
- CTI BioPharma · 1 shared drug class
- Celgene · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Azienda Ospedaliero, Universitaria Pisana:
- Azienda Ospedaliero, Universitaria Pisana pipeline updates — RSS
- Azienda Ospedaliero, Universitaria Pisana pipeline updates — Atom
- Azienda Ospedaliero, Universitaria Pisana pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Azienda Ospedaliero, Universitaria Pisana — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/azienda-ospedaliero-universitaria-pisana. Accessed 2026-05-17.